Usman Azam - 29 Sep 2025 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Reporting relationship
CHIEF EXECUTIVE OFFICER, Director
Issuer ticker
CUE
Reported as of
29 Sep 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 3 source fields
SEC form
4
Accepted by SEC
02 Oct 2025, 20:13:23 UTC
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Usman Azam by Michael Meluzio, attorney-in-fact

Key filing fact

Usman Azam filed Form 4 for Cue Biopharma, Inc. (CUE) on 02 Oct 2025.

Key facts

  • This page summarizes Usman Azam's Form 4 filing for Cue Biopharma, Inc. (CUE).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 02 Oct 2025, 20:13.

Change

  • No earlier filing in this sequence is available for direct comparison.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002089768 Primary reporting owner

Azam Usman

Relationship
CHIEF EXECUTIVE OFFICER, Director
Address
C/O CUE BIOPHARMA, INC., 40 GUEST STREET, BOSTON
Signature
/s/ Usman Azam by Michael Meluzio, attorney-in-fact
Signature date
02 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CUE transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+1,875,000
Change %
Price
$0.000000
Shares after
1,875,000
Date
29 Sep 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,875,000
Exercise price
$0.7200
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This stock option becomes exercisable in 48 monthly installments beginning on September 29, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .